Cytokine-induced Killer Study for Patients With Stage II Melanoma
NCT02498756
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Cytokine-induced killer cells
DRUG:
Ipilimumab
Sponsor
The First People's Hospital of Changzhou